Search
Search
About
Log in
Join
Experiences with
Ibrutinib
Posts
Communities
1,974 public posts
Filter results
Anyone know if CLL 10 trial (FCR v Ibrutinib+R) is open for recruitment anywhere in UK?
Mikey - I know you are on the trial, and you said recently that you thought it would be full by Christmas - can you tell me where you got that information please...I think I need to move very quickly, if it's not too late already to get a shot at the
ibrutinib
arm ...I've edited this post though because
Mikey - I know you are on the trial, and you said recently that you thought it would be full by Christmas - can you tell me where you got that information please...I think I need to move very quickly, if it's not too late already to get a shot at the
ibrutinib
arm ...I've edited this post though because
jibs60
in
CLL Support
11 years ago
Dr Rick Furman interviewed at IWCLL by Patient Power
Furman explains how a leading treatment candidate,
ibrutinib
, works.
[i]He also discusses whether there is concern that some patients may develop resistance to the drug and its effectiveness.
Furman explains how a leading treatment candidate,
ibrutinib
, works.
[i]He also discusses whether there is concern that some patients may develop resistance to the drug and its effectiveness.
AussieNeil
Partner
in
CLL Support
11 years ago
ABT-199 Trial experience in Australia
When I asked Andrew whether ABT-199 could help patients with Richter's Transformation, he responded that like
Ibrutinib
, it wouldn't work as a single therapy and in fact it had mostly stopped working when Richter's developed.
When I asked Andrew whether ABT-199 could help patients with Richter's Transformation, he responded that like
Ibrutinib
, it wouldn't work as a single therapy and in fact it had mostly stopped working when Richter's developed.
AussieNeil
Partner
in
CLL Support
11 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
This is NOT an approval,
it is the beginning of the approval process but only for two uses or indications... previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). http://online.wsj.com/article/PR-CO-20130829
This is NOT an approval,
it is the beginning of the approval process but only for two uses or indications... previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). http://online.wsj.com/article/PR-CO-20130829
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
I was about to start a course of Ibrutinib as a treatment naive patient and was told that I must wait until my anaemia was under control.
I have been told I must have two pints of blood transfused and a course of steroids, does anyone have any knowledge/experience of AIHA which is the possible cause of this fatigue/anaemia with a haemoglobin count of eight and no other symptoms since diagnosis eight years ago?
I have been told I must have two pints of blood transfused and a course of steroids, does anyone have any knowledge/experience of AIHA which is the possible cause of this fatigue/anaemia with a haemoglobin count of eight and no other symptoms since diagnosis eight years ago?
Berrytog
in
CLL Support
11 years ago
FDA application made for Ibrutinib in refractory/relapsed CLL/SLL ONLY
Janssen Research & Development, LLC announced the submission of a New Drug Application for
ibrutinib
to the U.S.
Janssen Research & Development, LLC announced the submission of a New Drug Application for
ibrutinib
to the U.S.
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Ibrutinib article includes info on leukaemia and lymphoma and how lymphocytes function
Interesting Gizmag article on
Ibrutinib
with some good background on how lymphocytes work and how CLL and MCL differ. (
Ibrutinib
trials were done on both). http://www.gizmag.com/lymphoma-treatment-cancer-
ibrutinib
/28085/ It is worth looking through the associated pictures.
Interesting Gizmag article on
Ibrutinib
with some good background on how lymphocytes work and how CLL and MCL differ. (
Ibrutinib
trials were done on both). http://www.gizmag.com/lymphoma-treatment-cancer-
ibrutinib
/28085/ It is worth looking through the associated pictures.
AussieNeil
Partner
in
CLL Support
11 years ago
A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia?
Editorial http://www.nejm.org/doi/pdf/10.1056/NEJMe1303054 Also published data on early
ibrutinib
trial...
Editorial http://www.nejm.org/doi/pdf/10.1056/NEJMe1303054 Also published data on early
ibrutinib
trial...
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Vkakoi strane v Evrope proischodet kliniceskije ispytanije s IBRUTINIB ( CLL 17p deletion)
Uncluding chronic lymphocystis leukomija 17 p deletion (CLL)
Uncluding chronic lymphocystis leukomija 17 p deletion (CLL)
deimante
in
CLL Support
11 years ago
Dr Sharman blogs on Cure for CLL & NHL?.... or just better control?
He observes that there have already been at least four cases of
ibrutinib
resistance and argues the case that a combined drug treatment will be necessary to avoid CLL/NHL developing resistance to new treatments.
He observes that there have already been at least four cases of
ibrutinib
resistance and argues the case that a combined drug treatment will be necessary to avoid CLL/NHL developing resistance to new treatments.
AussieNeil
Partner
in
CLL Support
11 years ago
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia...
This paper reviews the preclinical and clinical data for
ibrutinib
when used in the treatment of CLL. Recent studies showing the benefit of combination therapy using
ibrutinib
, monoclonal antibodies, and chemoimmunotherapy are also discussed. http://www.dovepress.com/getfile.php?fileID=16102
This paper reviews the preclinical and clinical data for
ibrutinib
when used in the treatment of CLL. Recent studies showing the benefit of combination therapy using
ibrutinib
, monoclonal antibodies, and chemoimmunotherapy are also discussed. http://www.dovepress.com/getfile.php?fileID=16102
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Dr Sharman begins blogging on relevant ASCO papers
http://www.cll-nhl.com/2013/05/
ibrutinib
-resistance.html Neil
http://www.cll-nhl.com/2013/05/
ibrutinib
-resistance.html Neil
AussieNeil
Partner
in
CLL Support
11 years ago
Winners And Losers in CLL at ASCO '13 - a marketing strategy consultant's perspective
He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (
Ibrutinib
) fared in their ASCO presentations and which companies with CLL drug development in
He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (
Ibrutinib
) fared in their ASCO presentations and which companies with CLL drug development in
AussieNeil
Partner
in
CLL Support
11 years ago
AACR Results Of Single Agent Ibrutinib from Dr. Wiestner of the NIH
Wiestner of the NIH on the one year data on single agent
ibrutinib
with no other drugs to help in 17p del and > 65 patients, with my commentary: http://bkoffman.blogspot.com/2013/05/
ibrutinib
-research-from-dr-wiestner-at.html Bottom line: 94% event free survival at one year. WOW!
Wiestner of the NIH on the one year data on single agent
ibrutinib
with no other drugs to help in 17p del and > 65 patients, with my commentary: http://bkoffman.blogspot.com/2013/05/
ibrutinib
-research-from-dr-wiestner-at.html Bottom line: 94% event free survival at one year. WOW!
bkoffman
CLL CURE Hero
in
CLL Support
11 years ago
Infinity Pharmaceuticals to report IPI-145 progress at ASCO 2013
Some company background from Oncology Business Review from February this year comparing Infinity with Pharmalytics (
Ibrutinib
): http://obroncology.com/forum/?
Some company background from Oncology Business Review from February this year comparing Infinity with Pharmalytics (
Ibrutinib
): http://obroncology.com/forum/?
AussieNeil
Partner
in
CLL Support
11 years ago
Avoiding Chemotherapy.
THIS is one reason why we need, and should push NICE, for the newer drugs such as
ibrutinib
. While the longer term effects of
ibrutinib
are not yet known, the damage to our genome is certainly less. Dick
THIS is one reason why we need, and should push NICE, for the newer drugs such as
ibrutinib
. While the longer term effects of
ibrutinib
are not yet known, the damage to our genome is certainly less. Dick
Kwenda
in
CLL Support
11 years ago
Interview with Dr. Adrian Wiestner from the NIH on his Research on Ibrutinib
Wiestner on his research on
ibrutinib
. His interviews will be the last from ASH 2012, as I look forward to going to ASCO 2013 and learning and sharing from that. Things are moving fast. Please take a look at http://bkoffman.blogspot.com and learn from Dr.
Wiestner on his research on
ibrutinib
. His interviews will be the last from ASH 2012, as I look forward to going to ASCO 2013 and learning and sharing from that. Things are moving fast. Please take a look at http://bkoffman.blogspot.com and learn from Dr.
bkoffman
CLL CURE Hero
in
CLL Support
11 years ago
Video, Dr. Jennifer Brown.... ibrutinib, idelalisib, and other agents.
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with
ibrutinib
, idelalisib, etc. http://tinyurl.com/ct7erqs
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with
ibrutinib
, idelalisib, etc. http://tinyurl.com/ct7erqs
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Clonal evolution, genomic drivers and effects of therapy in CLL
Karl Schwartz of Lymphomation.org has recently raised the important question of whether using drugs like
ibrutinib
to keep a lid on CLL might give a longer life expectancy than more traditional treatments that are likely to drive clonal evolution.
Karl Schwartz of Lymphomation.org has recently raised the important question of whether using drugs like
ibrutinib
to keep a lid on CLL might give a longer life expectancy than more traditional treatments that are likely to drive clonal evolution.
AussieNeil
Partner
in
CLL Support
11 years ago
Pharmacylics have closed their first Phase III Ibrutinib trial with 350 patients
The Wall Street Journal reports that Pharmacylics today announced that the enrollment target of 350 patients for its Phase III study using
ibrutinib
monotherapy versus ofatumumab in patients with relapsed or refractory CLL/SLL, has been achieved ahead of schedule and enrollments are now officially closed
The Wall Street Journal reports that Pharmacylics today announced that the enrollment target of 350 patients for its Phase III study using
ibrutinib
monotherapy versus ofatumumab in patients with relapsed or refractory CLL/SLL, has been achieved ahead of schedule and enrollments are now officially closed
AussieNeil
Partner
in
CLL Support
11 years ago
1
...
97
98
99
Next page
50
60
70
80
90
Filter results
Clear filters
Posted in
All communities
CLL Support
1885 results
CLL America Support
29 results
Non Hodgkin's Lymphoma Friends
29 results
View top 10 communities
Sort by
Most Relevant
Newest